ScholarIQanswers from OpenAlex

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

PaperCitations, authors & open-access status

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy have?

ScholarIQcitation count

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy has 8 citations in the OpenAlex counts ScholarIQ stores.

When was Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy published?

ScholarIQyear

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy has 2025 year in the ScholarIQ index.

What is the open-access status of Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy?

ScholarIQoa status

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy has green oa status in the ScholarIQ index.

What is the DOI of Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy?

ScholarIQdoi

The DOI for Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy is on the source record.

What is the PMID of Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy?

ScholarIQpmid

The PMID for Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy is on the source record.

What is the OpenAlex record for Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy?

ScholarIQopenalex

The OpenAlex for Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial